Physician profile
Brian M Heaster
NPI 1225010572
$2,844.24
in general payments reported to CMS, 2019-2025
25 companies · $627 in 2025
The $627 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $317 · 2021: $489 · 2022: $514 · 2023: $288 · 2024: $445 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,360.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $868.19 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $352.28 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $255.30 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $212.99 | 2019-2025 | |
| Amarin Pharma, INC. | $153.22 | 2020-2022 | |
| Corcept Therapeutics | $149.73 | 2024-2025 | Korlym |
| Pfizer INC. | $124.38 | 2021-2025 | |
| Abbvie INC. | $111.98 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $89.52 | 2023-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $78.40 | 2020-2025 | Jardiance, Zepbound |
| Esperion Therapeutics, INC. | $76.17 | 2025 | Nexletol |
| Shield Therapeutics INC | $42.65 | 2023-2024 | Accrufer |
| Abbott Laboratories | $38.55 | 2021-2022 | |
| Axsome Therapeutics, INC. | $32.77 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $32.62 | 2023-2024 | Gvoke Hypopen |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $30.15 | 2021-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $28.96 | 2025 | Voquezna |
| Astellas Pharma US INC | $27.22 | 2021-2022 | |
| Glaxosmithkline, LLC. | $27.05 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Insulet Corporation | $24.88 | 2024 | Omnipod |
| Sumitomo Pharma America, INC. | $21.99 | 2025 | Gemtesa |
| Irhythm Technologies, INC. | $18.08 | 2020 | |
| Boston Scientific Corporation | $17.63 | 2024 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $16.05 | 2025 | Capvaxive, Gardasil 9 |
| Exact Sciences Corporation | $13.48 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Heaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.